Primary aim of this study is to assess the feasibility of conducting clinical research for
delirium (confusion due to medical problems) at Clements University Hospital in Dallas,
Texas. A secondary aim is to assess whether an FDA-approved sleeping aid called Ramelteon or
an over-the-counter supplement called Citicoline are safe and beneficial in delirium.
The primary purpose of this study is to investigate the effects of bedtime administration of
a single dose of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on next-morning on-road
driving performance. In addition, the drugs' effects on balance are evaluated during the
night, and the next morning residual effects on memory and psychomotor performance.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.